Fosmanogepix - Basilea Pharmaceutica
Alternative Names: APX-001; E-1211; E-210; PF-07842805Latest Information Update: 31 May 2024
At a glance
- Originator Eisai Co Ltd
- Developer Amplyx Pharmaceuticals
- Class Aminopyridines; Antifungals; Antineoplastics; Oxazoles; Phosphates; Small molecules
- Mechanism of Action GWT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Aspergillosis; Candidaemia
- No development reported Acute myeloid leukaemia; Coccidioidomycosis; Mycoses
Most Recent Events
- 29 May 2024 Basilea Pharmaceutica initiates an expanded access programme to fosmanogepix for Invasive fungal infections (PO, tablets) (IV, Infusion) (NCT06433128)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Mycoses(In volunteers) in USA (PO)
- 05 Jan 2024 Basilea Pharmaceutica plans a phase III trial for invasive mold infections by end of 2024